Structure Therapeutics (NASDAQ:GPCR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01, Zacks reports.
Structure Therapeutics Stock Performance
NASDAQ GPCR traded up $2.94 during trading hours on Thursday, hitting $22.82. The company had a trading volume of 1,591,478 shares, compared to its average volume of 797,217. Structure Therapeutics has a 1-year low of $19.61 and a 1-year high of $62.74. The company has a market cap of $1.31 billion, a PE ratio of -30.84 and a beta of -2.75. The business has a 50 day moving average of $26.80 and a 200-day moving average of $33.74.
Wall Street Analyst Weigh In
GPCR has been the topic of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $81.29.
About Structure Therapeutics
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
See Also
- Five stocks we like better than Structure Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- 3 Warren Buffett Stocks to Buy Now
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Stock Sentiment Analysis: How it Works
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
